
Tango Therapeutics (TNGX) Stock Forecast & Price Target
Tango Therapeutics (TNGX) Analyst Ratings
Bulls say
Tango Therapeutics is a promising biotechnology company with a strong pipeline of precision oncology therapies. Their focus on discovering novel drug targets for the treatment of cancer, particularly in the areas of KRAS and PRMT5, makes them a key player in the competitive biotech market. With partnerships and promising data in both pancreatic and lung cancer, the company has the potential for rapid growth and success in the near future. As a result, Tango Therapeutics has a positive outlook, and their stock may be a good investment opportunity.
Bears say
Tango Therapeutics is facing a crowded field in the biotechnology industry, with at least 20 competitors in the KRAS inhibitor space. Additionally, the company may need to access both dilutive and non-dilutive financing options to support operations, which could lead to ownership dilution for investors. Furthermore, there is potential for delayed FDA approval or negative clinical results for their lead asset, TNG462, which could significantly impact the company's financials and stock performance.
This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Tango Therapeutics (TNGX) Analyst Forecast & Price Prediction
Start investing in Tango Therapeutics (TNGX)
Order type
Buy in
Order amount
Est. shares
0 shares